Share on StockTwits

BioMarin Pharmaceutical (NASDAQ:BMRN) released its earnings data on Wednesday. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.18, AR Network reports. The company had revenue of $191.70 million for the quarter, compared to the consensus estimate of $159.70 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 40.1% on a year-over-year basis.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 0.10% during mid-day trading on Wednesday, hitting $61.09. 1,083,353 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $55.04 and a 52 week high of $84.25. The stock’s 50-day moving average is $61.17 and its 200-day moving average is $65.86. The company’s market cap is $8.915 billion.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Friday, July 4th. They now have a $68.00 price target on the stock. On the ratings front, analysts at Credit Suisse upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. They now have a $73.00 price target on the stock, up previously from $61.74. Nine analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $81.07.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.